# ![@canoebrookbl Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1341917218481860608.png) @canoebrookbl canoebrookbl

canoebrookbl posts on X about $qure, data, $xbi, dr the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1341917218481860608/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1341917218481860608/c:line/m:interactions.svg)

- [--] Week [-----] -69%
- [--] Month [------] +63%
- [--] Months [-------] +61,417%

### Mentions: [--] [#](/creator/twitter::1341917218481860608/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1341917218481860608/c:line/m:posts_active.svg)

- [--] Week [--] -41%
- [--] Month [--] +6.90%
- [--] Months [---] +10,560%

### Followers: [---] [#](/creator/twitter::1341917218481860608/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1341917218481860608/c:line/m:followers.svg)

- [--] Week [---] -0.53%
- [--] Month [---] +7.10%
- [--] Months [---] +235%

### CreatorRank: [---------] [#](/creator/twitter::1341917218481860608/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1341917218481860608/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  23.01% [stocks](/list/stocks)  14.16% [social networks](/list/social-networks)  4.42% [technology brands](/list/technology-brands)  4.42% [countries](/list/countries)  1.77% [financial services](/list/financial-services)  0.88%

**Social topic influence**
[$qure](/topic/$qure) #16, [data](/topic/data) 11.5%, [$xbi](/topic/$xbi) #34, [dr](/topic/dr) 9.73%, [if you](/topic/if-you) 7.96%, [$insm](/topic/$insm) 6.19%, [$bhvn](/topic/$bhvn) 6.19%, [science](/topic/science) 5.31%, [opinion](/topic/opinion) 5.31%, [based](/topic/based) 5.31%

**Top accounts mentioned or mentioned by**
[@usfda](/creator/undefined) [@vprasadmdmph](/creator/undefined) [@potus](/creator/undefined) [@drmakaryfda](/creator/undefined) [@youtube](/creator/undefined) [@alecgaffney](/creator/undefined) [@rarediseases](/creator/undefined) [@lauraloomer](/creator/undefined) [@senateaging](/creator/undefined) [@senrickscott](/creator/undefined) [@sengillibrand](/creator/undefined) [@logicalvaluemx](/creator/undefined) [@desertdweller93](/creator/undefined) [@petermantas](/creator/undefined) [@biggercapital](/creator/undefined) [@uniqurenv](/creator/undefined) [@robertkennedyjr](/creator/undefined) [@hdatweeting](/creator/undefined) [@realdonaldtrump](/creator/undefined) [@biopharmadive](/creator/undefined)

**Top assets mentioned**
[uniQure N.V. (QURE)](/topic/$qure) [Insmed, Inc. (INSM)](/topic/$insm) [Biohaven Pharmaceutical Holding Company Ltd. (BHVN)](/topic/$bhvn) [Olema Pharmaceuticals, Inc. (OLMA)](/topic/$olma) [Novartis AG (NVS)](/topic/$nvs) [Abivax SA (ABVX)](/topic/$abvx) [Celcuity Inc. Common Stock (CELC)](/topic/$celc) [Monte Rosa Therapeutics, Inc. (GLUE)](/topic/$glue) [Eli Lilly and Company (LLY)](/topic/$lly) [Terns Pharmaceuticals, Inc. (TERN)](/topic/$tern) [Enliven Therapeutics, Inc. (ELVN)](/topic/$elvn) [Pfizer, Inc. (PFE)](/topic/$pfe) [Revolution Medicines, Inc. (RVMD)](/topic/$rvmd) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Novo-Nordisk (NVO)](/topic/$nvo) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Western Digital Corp (WDC)](/topic/$wdc) [Snowflake Inc. (SNOW)](/topic/$snow) [Palantir Technologies Inc. (PLTR)](/topic/$pltr) [AppLovin Corporation (APP)](/topic/$app) [Protagonist Therapeutics, Inc (PTGX)](/topic/$ptgx)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$qure a 5% holder (standard life) adding another 25% of its holdings"  
[X Link](https://x.com/canoebrookbl/status/2012307039058542703)  2026-01-16T23:32Z [---] followers, [----] engagements


"$SNYs venglustat failed phase [--] is a big deal. Not much innovation in the non gene therapy area for Fabry disease"  
[X Link](https://x.com/canoebrookbl/status/2018384812986503228)  2026-02-02T18:03Z [---] followers, [---] engagements


"$olma if you know breast cancer this is the easiest money from $18 post Roche data in less than [--] m. Still has a lot of room to run. JPM TP $55"  
[X Link](https://x.com/canoebrookbl/status/1999580269507150311)  2025-12-12T20:41Z [---] followers, [---] engagements


"$olma NVS or PFE acquisition target in [----] Target market cap$celc"  
[X Link](https://x.com/canoebrookbl/status/2000591103205208188)  2025-12-15T15:37Z [---] followers, [---] engagements


"$glue MRT-8102 data look great. Meaningfully better than canakinumab in terms of CRP reduction and perhaps better and differentiated from NLRP3 inhibitors. CV indication worth$5B but needs8K patients phase [--]. $NVS buyout target. Q is $OLMA first"  
[X Link](https://x.com/canoebrookbl/status/2009113010854613484)  2026-01-08T04:00Z [---] followers, [---] engagements


"$tern has more downside risks now with $elvn positive data even though they have different binding targets. Broadly speaking they are still competitors and $tern is a bit too pricey"  
[X Link](https://x.com/canoebrookbl/status/2009350548026486996)  2026-01-08T19:44Z [---] followers, [---] engagements


"$insm BRINSUPRI the beat continues leaving room for future beats. Several clinical milestones this year are also important. Very impressive execution"  
[X Link](https://x.com/canoebrookbl/status/2009632470287937765)  2026-01-09T14:24Z [---] followers, [---] engagements


"$olma buyout next week $NVS or $PFE"  
[X Link](https://x.com/canoebrookbl/status/2009723311337488762)  2026-01-09T20:25Z [---] followers, [---] engagements


"JPM call $rvmd will dominate and $mrk may not be the only bidder. Value could be over $30B if no deal announced this weekend. Smaller deals could be announced during the conference. $olma looks attractive (to NVS PFE) as Roche added about $60 B to its MC since adjuvant BC data"  
[X Link](https://x.com/canoebrookbl/status/2010059030186865108)  2026-01-10T18:39Z [---] followers, [----] engagements


"$insm why does its CEO keep sandbagging Brinsupri launch by not providing guidance Positioning for M&A or they can beat 100-200% each quarter in 2026"  
[X Link](https://x.com/canoebrookbl/status/2012559898790240558)  2026-01-17T16:17Z [---] followers, [---] engagements


"$abvx still targets $60s by Q1 early Q2. Very much a failed strategic review of an undifferentiated asset. Will see in less than [--] months"  
[X Link](https://x.com/canoebrookbl/status/2015137907607286257)  2026-01-24T19:01Z [---] followers, [----] engagements


"Relentless OTM option buying if continues today could drive $qure positive"  
[X Link](https://x.com/canoebrookbl/status/2019071853541683252)  2026-02-04T15:33Z [---] followers, [---] engagements


"At least no one can compound AMT-130 [---] [---] if they are approved someday $Hims is killing $lly and $nvo until it gets sued"  
[X Link](https://x.com/canoebrookbl/status/2019438787798221295)  2026-02-05T15:51Z [---] followers, [---] engagements


"$qure attention is on HD and [---] but [---] generated some interesting data in the most severe type of Fabry disease where unmet need is high. These are classical Fabry disease male patients who do not respond well to ERT. Will have to see lower dose efficacy "  
[X Link](https://x.com/canoebrookbl/status/2019777211180482937)  2026-02-06T14:16Z [---] followers, [----] engagements


"$abvx down day on big index up Potential takeunder lower than current price"  
[X Link](https://x.com/canoebrookbl/status/2019791289043271896)  2026-02-06T15:12Z [---] followers, [---] engagements


"$abvx why is it takeunder When is the CD launch Only 5y composite of matter plus [--] m for US exclusivity. No one is doing BO based on use patent. So obe is pretty much an UC drug currently without maintenance data"  
[X Link](https://x.com/canoebrookbl/status/2019799882786308352)  2026-02-06T15:46Z [---] followers, [---] engagements


"I can see why no pharma wants ST-920 if you have to exclude AAV6 neutralizing ab positive patients that could be half in certain regions and a lot of money to test everyone. L dose [---] seems to have slightly higher a GAL raising potency. Maybe able to monetize soon"  
[X Link](https://x.com/canoebrookbl/status/2020207715482759566)  2026-02-07T18:47Z [---] followers, [---] engagements


"$wdc never too late was in the name since last fall. $WDC and $snow both still a buy. A family member declined post-college finance positions with these two firms last summer. $WDC best performing S&P [---] stock until Friday November [--] https://t.co/06BOe3TDqQ $WDC and $snow both still a buy. A family member declined post-college finance positions with these two firms last summer. $WDC best performing S&P [---] stock until Friday November [--] https://t.co/06BOe3TDqQ"  
[X Link](https://x.com/canoebrookbl/status/2020328787242807578)  2026-02-08T02:48Z [---] followers, [---] engagements


"AMT-191 has the best -Gal A enzyme raising data (27-208 fold higher than normal range) in n=4. It is a matter of enrolling more pts and follow up on typical endpoints and FDA interactions. But it is the best pipeline drug for Fabry disease. $qure maybe able to monetize this"  
[X Link](https://x.com/canoebrookbl/status/2018383459669196876)  2026-02-02T17:58Z [---] followers, [----] engagements


"JPM is adding even more than GS. What do they know Waiting for Fidelity"  
[X Link](https://x.com/canoebrookbl/status/2021606295380385837)  2026-02-11T15:24Z [---] followers, [---] engagements


"$qure ($14 to $250 or higher) will outperform $PLTR ($10-180) $app ($60-700) all happening in 18m. Stay tuned"  
[X Link](https://x.com/anyuser/status/1973181205307908304)  2025-10-01T00:20Z [---] followers, [----] engagements


"$qure biotech buyout deal flow continues with JNJ buying $Ptgx and BMS buying Orbital Therapeutics. With a groundbreaking gene therapy for HD a deadly neurodegenerative disease Uniqure will command a much higher premium than recent announced deals"  
[X Link](https://x.com/anyuser/status/1976705156193661171)  2025-10-10T17:43Z [---] followers, [---] engagements


"If $NVS is paying $12B for a phase [--] asset with peak sales forecasts of $2-4B how much will $qure fetch in a buyout $15-20B is a bargain https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline https://www.novartis.com/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline"  
[X Link](https://x.com/anyuser/status/1982497508959084803)  2025-10-26T17:20Z [---] followers, [----] engagements


"$insm I am speechless. What a performance Almost 9x since positive ph [--] brensocatib data but remember the golden rule: 20-25x to 1st peak since positive of 1st major drug 2-3x from current level. One day $qure will become $insm: a $35B co.& beat and raise 10% jump Way to go"  
[X Link](https://x.com/anyuser/status/1983876481718874240)  2025-10-30T12:39Z [---] followers, [----] engagements


"$qure suggest to read his tweet carefully as comments from a discussant. Michael Okun MD: Executive Director of the Fixel Institute for Neurological Diseases at the University of Florida (UF Health) and a leading expert in movement disorders (including HD and Parkinsons) Striking new data were presented from the AMT-130 gene therapy program for Huntingtons disease at the Movement Disorders Society meeting in Hawaii this morning Thanks to Dr. Deborah Hall from Rush for bringing us the breaking data beyond just the press release. This https://t.co/uoRmeHSnqL Striking new data were presented"  
[X Link](https://x.com/anyuser/status/1986689729606393879)  2025-11-07T06:58Z [---] followers, [----] engagements


"$qure UniQure FDA fiasco more heart breaking for these families than investors. Senate hearing and FDA should listen to their stories We need to balance my version of science is the only version with patient access to rare disease medicines/hope https://curehd.blogspot.com/2025/10/as-hopes-build-about-first-effective.htmlm=1 https://curehd.blogspot.com/2025/10/as-hopes-build-about-first-effective.htmlm=1"  
[X Link](https://x.com/anyuser/status/1987206871409971491)  2025-11-08T17:13Z [---] followers, [----] engagements


"$qure $xbi less conservative Bloomberg opinion has similar harsh view on the US FDA. Highlighted toward the end of the article. An intensified media scrutiny from united mainstream media"  
[X Link](https://x.com/anyuser/status/1987302692964958242)  2025-11-08T23:34Z [---] followers, [----] engagements


"After watching the beginning of this MM interview regarding rare disease I think VP will take the hit on HD and $qure and rare disease biological/gene therapy and leave @US_FDA permanently very soon RFK will probably save MM this time. via @YouTube https://youtu.be/-ZKkXlFR8FQsi=Y4JyqoY0Q6woiNOY https://youtu.be/-ZKkXlFR8FQsi=Y4JyqoY0Q6woiNOY"  
[X Link](https://x.com/anyuser/status/1987580068613488704)  2025-11-09T17:56Z [---] followers, [----] engagements


"No VP confirmed thanks @AlecGaffney $crsp CEO is invited. Hopefully MABA will cover @RareDiseases gene therapies like $qure. But this Summit is certainly driving up $xbi and most biotech stocks up Some interesting session titles in the mix here like Makary speaking on the Future of the FDA and a session on making biotech accelerate. Makary tends to bundle policy announcements with big events like this. https://t.co/Nksrk6i9L2 Some interesting session titles in the mix here like Makary speaking on the Future of the FDA and a session on making biotech accelerate. Makary tends to bundle policy"  
[X Link](https://x.com/anyuser/status/1988336919764402473)  2025-11-11T20:03Z [---] followers, [----] engagements


"@LauraLoomer Dear Laura as VP continues to stifle US bio innovation/patient access to innovative gene therapies like AMT-130 by $qure can you use your enormous media influence for the better future of the American people @VPrasadMDMPH https://www.newsweek.com/laura-loomer-fda-vaccine-chief-vinay-prasad-2111358 https://www.newsweek.com/laura-loomer-fda-vaccine-chief-vinay-prasad-2111358"  
[X Link](https://x.com/anyuser/status/1988351390985711746)  2025-11-11T21:01Z [---] followers, [----] engagements


"$legn another example of failed strategic review down from $58 in mid [----] to $17 and change now"  
[X Link](https://x.com/canoebrookbl/status/2016721129386496464)  2026-01-29T03:52Z [---] followers, [---] engagements


"$glue will come back once people realize ziltivekimab has similar potency in hs-CRP reduction (longer duration data) and [--] years ahead with readout later this year. The phase [--] has 7K pts so shooting for a much better HR than canakizumab"  
[X Link](https://x.com/canoebrookbl/status/2010073769340199042)  2026-01-10T19:38Z [---] followers, [---] engagements


"@unknown_tester_ You know our friend Peter Marks is a Sr. VP at $lly a not so senior title at one of the BP hard to imagine VP a less senior person than PM is single handedly destroying the whole US pharma/biotech innovations by at least [--] years VP and MM must be gone Let us make it happen"  
[X Link](https://x.com/canoebrookbl/status/2022481645203533923)  2026-02-14T01:22Z [---] followers, [---] engagements


"$qure most investors do not understand the importance to have a deal like NVS. ABBV bought PCYC$20B for half of US and ex-US royalties. AMT-130 will be much bigger than Imbruvica with no competition. $500 is a discount even without a broad label right away"  
[X Link](https://x.com/canoebrookbl/status/1972440180943737070)  2025-09-28T23:15Z [---] followers, [---] engagements


"$qure benchmark AveXis acquisition by NVS@8.7B the acquisition price for $qure could top $20-25B (and still make the model work) as SMA is a much smaller than HD. It is a bit more challenging to commercialize at scale initially but you will avoid the liver tox with AAV"  
[X Link](https://x.com/canoebrookbl/status/1971784641888829779)  2025-09-27T03:51Z [---] followers, [----] engagements


"$qure poorly written Forbes piece titled QURE Stock to $500. I do agree QURE has a shot at $500 if management does not screw up (not guaranteed). You need 4K patient @2.5M to reach peak sales of $10B a conservative base forecast for big pharma assuming broad HD label"  
[X Link](https://x.com/canoebrookbl/status/1972139655710888210)  2025-09-28T03:21Z [---] followers, [----] engagements


"$qure DD on C-level. Given Matts roots in IB and CFO post at device co very confident on my call for an US co-promote and ex-US licensing deal to de-risk launch between JPM and approval. Full acquisition in [--] years post approval. Reiterate $500 target with broad HD label"  
[X Link](https://x.com/anyuser/status/1972403769175597151)  2025-09-28T20:51Z [---] followers, [---] engagements


"$qure when you see typically more reserved British PIs and the BBC medical editor showing such excitement and softly demanding NHS to pay over 2M for this you know this is truly a breakthrough and the media fever will come here is the US soon beyond biotech"  
[X Link](https://x.com/canoebrookbl/status/1972433981988807037)  2025-09-28T22:51Z [---] followers, [----] engagements


"$qure further DD no CBO at qure so Matts IB friends and Centerview are probably calling him directly. Institutions likely to fake a couple of bucks down early tomorrow and then run this up past $150 into JPM to position for a $250 acquisition"  
[X Link](https://x.com/anyuser/status/1972493755073839345)  2025-09-29T02:48Z [---] followers, [----] engagements


"$qure HD breakthrough positions quer to break ATH@$78 in 2w break 95-100 by Halloween. Earning on Nov.5 followed by pre-BLA and anticipation of JPM sets up $150. Price discovery after JPM deal 80-100% premium. No deal wait for filing and consolidate. My base case scenario"  
[X Link](https://x.com/canoebrookbl/status/1972857250877436008)  2025-09-30T02:53Z [---] followers, [---] engagements


"$qure while HD is in the spotlight MTLE data in 1H [----] could be another major kicker just like $insm while waiting for Brensocatib approval TPIP showed best-in-class potential. One two punch plus acquisition way to go"  
[X Link](https://x.com/anyuser/status/1973200254611943777)  2025-10-01T01:36Z [---] followers, [----] engagements


"$qure people ask me the theoretical blue sky valuation of qure: if both HD and MTLE work peak sales $20 B 5x multiple at around $100B. But you need a partner to achieve that so 50% left. But I fully believe if a $15-16 B buyout is available around JPM it will be taken"  
[X Link](https://x.com/anyuser/status/1973453849760506148)  2025-10-01T18:23Z [---] followers, [----] engagements


"$qure shareholders let us crush those shorts tomorrow and skyrocket shares for a deal at JPM @250 or higher"  
[X Link](https://x.com/canoebrookbl/status/1973550436251738265)  2025-10-02T00:47Z [---] followers, [----] engagements


"$qure 1st AMT-130 pivotal data presentation at a medical conference. Should be interesting from an US investigator perspective and add some color to Uniqures company presentation. It is coming in [--] days Some big pharmas to mingle with as well"  
[X Link](https://x.com/anyuser/status/1973894899763421402)  2025-10-02T23:36Z [---] followers, 10.6K engagements


"$qure [--] Y old video. Breaking News with Dr Sung; Wave PTC uniQure Generation HD [--] and more via @YouTube. He is a very good speaker who should provide a solid US perspective re AMT-130 on Sun. No worry about competitions as some neg. analysts suggested. https://youtu.be/jHk9wZOR3VAsi=UUnhKRyN8_clFV9_ https://youtu.be/jHk9wZOR3VAsi=UUnhKRyN8_clFV9_"  
[X Link](https://x.com/anyuser/status/1974321078450467102)  2025-10-04T03:50Z [---] followers, [----] engagements


"$qure registration for HSG annual meeting (Dr. Sungs [---] data presentation) was full when I found out about the conference in Nashville a few days ago. If you happen to attend please post on X and it will be popular"  
[X Link](https://x.com/canoebrookbl/status/1974329583790174552)  2025-10-04T04:23Z [---] followers, [----] engagements


"$qure super important to hear his talk on Sun. I trust qures [--] US COE number and Tabrizis couple of U.K. COE quote. US more advanced in clinical/procedure. UK translational research (most of Tabrizis talk). This is why I can not tolerate no press release from qure"  
[X Link](https://x.com/canoebrookbl/status/1974846339403190654)  2025-10-05T14:37Z [---] followers, [----] engagements


"$qure love the passion of this retail investor group on X. It is like we are doing HD disease awareness campaign on X on a daily basis. Like @ericjacksons $40M/day campaign for $open"  
[X Link](https://x.com/canoebrookbl/status/1974858871312449758)  2025-10-05T15:27Z [---] followers, [---] engagements


"$qure expect more upgrades like this throughout this week and next post Dr. Sungs presentation. H.C. Wainwright QURE's PT to $110 from $70. Time to add Jan. Apr. calls as swing and non biotech investors chasing Plug and Iren. GS upgrade will significantly drive up price"  
[X Link](https://x.com/anyuser/status/1975244600249114673)  2025-10-06T16:59Z [---] followers, [----] engagements


"$qure this is how smart investors pick up what we do here on X and took actions and benefited from it"  
[X Link](https://x.com/anyuser/status/1975691967507144869)  2025-10-07T22:37Z [---] followers, [----] engagements


"$qure after Dr. Sungs presentation and standing ovation from conference attendees GS reluctantly raised its PT to $120"  
[X Link](https://x.com/anyuser/status/1975704222789468643)  2025-10-07T23:26Z [---] followers, [----] engagements


"$qure like celg regn gild from right before positive pivotal for the 1st major drug for that co. to the 1st major peak of the stock you have 20-25x. $qure $14-300 at least it will come. You take much less risks by focusing on $qure and $insm etc"  
[X Link](https://x.com/canoebrookbl/status/1976313006306050342)  2025-10-09T15:45Z [---] followers, [----] engagements


"$insm $qure investors curtain call the two biggest biotech buyouts ($50B and $20B) are coming position your portfolios accordingly"  
[X Link](https://x.com/anyuser/status/1976708971844300877)  2025-10-10T17:58Z [---] followers, [----] engagements


"$qure green candles after Dr. Sungs talk is possible on Mon. (down market at least initially) as qures announcement left out a lot of details that gives more sci/clinical minded investors hesitations. Note previous article I shared re surgery UAB is more advanced than UCL"  
[X Link](https://x.com/anyuser/status/1977066767064383682)  2025-10-11T17:40Z [---] followers, [---] engagements


"$qure not getting ahead ourselves too much but if Uniqure does get bought out at a significant premium will set up another poll to see if we should set up a foundation for HD and if we have strong poll results then we will do it"  
[X Link](https://x.com/anyuser/status/1977400443732217951)  2025-10-12T15:46Z [---] followers, [----] engagements


"$kura $celc my small ESMO plays look like both will pop on Monday question is by how much. We will see"  
[X Link](https://x.com/anyuser/status/1979657592503963777)  2025-10-18T21:15Z [---] followers, [----] engagements


"$qure why naysayers still doubt pivotal ph 1/2 size and using nat history/L dose as control arm The FDA approval of Zolgensma for patients 2Y with SMA was based on data from the ph [--] START trial of [--] symptomatic SMA Type [--] infants. Natural history data supportive of approval"  
[X Link](https://x.com/canoebrookbl/status/1981153758605431069)  2025-10-23T00:20Z [---] followers, [---] engagements


"$qure We are all smart money in certain areas and dumb money in others. When you have a lot of investors who have no industry/biotech expertise they question common knowledge assumed by industry experts. But you got to listen to them if there are enough uninformed investors"  
[X Link](https://x.com/canoebrookbl/status/1981155218319692157)  2025-10-23T00:26Z [---] followers, [---] engagements


"To $qure investors my advice is to follow smart money: Dr. Sung Wild and Tabrizi but open to hear out other opinions. Because if you have enough uninformed investors you do not want to be overly aggressive and get hurt by the dumb money. Only risk is Uniqures execution"  
[X Link](https://x.com/canoebrookbl/status/1981575407192395962)  2025-10-24T04:16Z [---] followers, [----] engagements


"@Kumodong_Li Very unlikely for a localized delivery to have liver toxicity caused by systemic exposure. Ignore noises"  
[X Link](https://x.com/canoebrookbl/status/1982804772429205686)  2025-10-27T13:41Z [---] followers, [---] engagements


"$qure watch out for the David Meek Factor if he is named Executive Chairman and CEO by year end my 2Y $qure target price is raised to $1000. We shall see"  
[X Link](https://x.com/canoebrookbl/status/1983189194697781282)  2025-10-28T15:08Z [---] followers, [----] engagements


"$qure UniQure investors $70 is only the 1st step. With breakthrough HD data $XBI recovering buoyant M&A environment ATH in days. Thanks for focusing and ignoring short hedge funds planted series of fabricated negative articles. Go UniQure"  
[X Link](https://x.com/canoebrookbl/status/1983213709741760771)  2025-10-28T16:46Z [---] followers, [----] engagements


"$qure fam I am going to see G5 tomorrow at Dodgers Stadium. Should be an exciting game"  
[X Link](https://x.com/canoebrookbl/status/1983377960603427018)  2025-10-29T03:38Z [---] followers, [----] engagements


"Eventually $qure will become my other top holdings $insm almost all shares are owned by institutions and very few on X talk about it because retail investors were happy with 5x and sold trimmed too early. Hope you will be the few left on X still holding $qure at $350"  
[X Link](https://x.com/anyuser/status/1983640606577672282)  2025-10-29T21:02Z [---] followers, [----] engagements


"The goal of our biotech investing should be to identify the new [--] horsemen and stick with them and allow them to grow. The rest is just for fun pain and ego and should not exceed 5-10% of your biotech portfolio. Biotech is coming back and the new [--] horsemen will be identified"  
[X Link](https://x.com/anyuser/status/1984676761192579463)  2025-11-01T17:39Z [---] followers, [----] engagements


"$qure a huge setback for the HD community As I tweeted before there were signs of significant red flags: insider selling significant portions of holdings and NO PR for key data presentation. Setback is temporary a regulatory path will be set for 130.Time for David to step in"  
[X Link](https://x.com/canoebrookbl/status/1985341462054326301)  2025-11-03T13:41Z [---] followers, [----] engagements


"$qure will be interesting to monitor how Jennison Associates will disclose its uniQure positions. Nearly [--] m shares bought recently in the high $50 and most recent at $70. Are they adding more today with their position already close to 4% of its healthcare fund"  
[X Link](https://x.com/anyuser/status/1985544778814271565)  2025-11-04T03:08Z [---] followers, [----] engagements


"FDA Expedited Programs for Regenerative Medicine Therapies for Serious Conditions Draft Guidance for Industry: September [----] Read the highlighted paragraphs. Using phase 1/2 with external control should not be a problem for AA. Why did FDA tell $qure not aligned anymore"  
[X Link](https://x.com/anyuser/status/1985871904595710368)  2025-11-05T00:48Z [---] followers, 20.4K engagements


"Pure politics and dysfunctional FDA"  
[X Link](https://x.com/canoebrookbl/status/1985872735810306530)  2025-11-05T00:52Z [---] followers, [---] engagements


"I am pretty sure HD ($qure) and SCA ($bhvn) patients and families will bring the new FDA guidelines with paragraphs highlighted in my post and call these politicians and perhaps people close to POTUS and ask him to completely reorganize the US FDA"  
[X Link](https://x.com/canoebrookbl/status/1985894867835465968)  2025-11-05T02:20Z [---] followers, [----] engagements


"Do some of these senior US FDA officials work for China They want to tank or slow down the US biotech innovation so China can take the lead"  
[X Link](https://x.com/canoebrookbl/status/1985907206353797139)  2025-11-05T03:09Z [---] followers, [---] engagements


"After reading todays top $qure comments seems all questions can be addressed by the draft new FDA guideline in favor of uniQure. Suggest not to get emotional and wait for the FDA minutes. uniQures press release is not clear what the problem really is so as analysts comments. FDA Expedited Programs for Regenerative Medicine Therapies for Serious Conditions Draft Guidance for Industry: September [----] Read the highlighted paragraphs. Using phase 1/2 with external control should not be a problem for AA. Why did FDA tell $qure not aligned anymore https://t.co/dR4iabxQTu FDA Expedited Programs for"  
[X Link](https://x.com/anyuser/status/1986078724081770867)  2025-11-05T14:30Z [---] followers, [----] engagements


"@laurencurehd @Help4HDI $qure investors please join Lauren and Katie if you can to help rally the HD community"  
[X Link](https://x.com/anyuser/status/1986208689041318389)  2025-11-05T23:07Z [---] followers, [---] engagements


"Contact U.S. Senator Bill Cassidy pretty sure the HD community and $qure shareholders have reached out to Bill Cassidy MD already https://www.cassidy.senate.gov/contact/ https://www.cassidy.senate.gov/contact/"  
[X Link](https://x.com/canoebrookbl/status/1986234339211026947)  2025-11-06T00:49Z [---] followers, [----] engagements


"$xbi $bhvn $qure looks like the US senate has been mobilized already pretty sure Bill Cassidy MD will weigh in as well for HD SCA and rare disease communities so that the American people do not have to go to Japan to get Ceredist an old drug for their SCA $qure $bhvn $xbi Looks like the hearing (link) will cover this issue. Ive put brief bios for the Chair and Ranking Member at the end of the thread. https://t.co/GTXaTvmaD7 $qure $bhvn $xbi Looks like the hearing (link) will cover this issue. Ive put brief bios for the Chair and Ranking Member at the end of the thread. https://t.co/GTXaTvmaD7"  
[X Link](https://x.com/anyuser/status/1986249997906813091)  2025-11-06T01:51Z [---] followers, [----] engagements


"@SenateAging @US_FDA @SenRickScott @SenGillibrand @DrMakaryFDA $xbi $qure$bhvn investors HD SCA rare disease pts/caregivers stay calm and focused if you are in the US speak out and let your voice heard together we keep US biotech innovation moving forward. If you are outside of the US be a little patient and let the US system work"  
[X Link](https://x.com/anyuser/status/1986264459216888166)  2025-11-06T02:48Z [---] followers, [----] engagements


"$qure $bhvn $xbi hot button issues are main topics of the upcoming hearing on the rare disease drug development pipeline regulatory barriers and explore how the FDA can better support innovation while maintaining the highest standards of safety and scientific integrity"  
[X Link](https://x.com/anyuser/status/1986271900876861460)  2025-11-06T03:18Z [---] followers, [----] engagements


"@SenateAging @SenRickScott @US_FDA @SenGillibrand @DrMakaryFDA Senator Scott Gillibrand and Dr. Makary recent FDA rigid approval reviews of gene therapies are inconsistent with the flexibility shown in the draft FDA guideline please insure patient access to rare disease medicines and biotechs continuous commitment to R&D in rare diseases"  
[X Link](https://x.com/anyuser/status/1986320501808189880)  2025-11-06T06:31Z [---] followers, [---] engagements


"$qure important to hear US KOLs like Dr. Ole Isacson who is not a AMT-130 investigators from Science one of the most authoritative journals. His unique academic clinical and industry background adds even more credibility. https://www.science.org/doi/10.1126/science.aec7429 https://www.science.org/doi/10.1126/science.aec7429"  
[X Link](https://x.com/anyuser/status/1986470837822890335)  2025-11-06T16:28Z [---] followers, [----] engagements


"A balanced view but Dr. Henry Miller called AMT-130 a tour de force of delicate brain surgery and molecular biology. These non [---] investigator KOLs opinions weigh heavily on FDA and even senate hearings https://henrymillermd.org/30422/treating-huntingtons https://henrymillermd.org/30422/treating-huntingtons"  
[X Link](https://x.com/anyuser/status/1986507333959360941)  2025-11-06T18:53Z [---] followers, [----] engagements


"$qure strong US (non AMT-130investigator) KOL support A balanced view but Dr. Henry Miller called AMT-130 a tour de force of delicate brain surgery and molecular biology. These non [---] investigator KOLs opinions weigh heavily on FDA and even senate hearings https://t.co/aAwfaYDSTO A balanced view but Dr. Henry Miller called AMT-130 a tour de force of delicate brain surgery and molecular biology. These non [---] investigator KOLs opinions weigh heavily on FDA and even senate hearings https://t.co/aAwfaYDSTO"  
[X Link](https://x.com/anyuser/status/1986526624498786808)  2025-11-06T20:10Z [---] followers, [----] engagements


"$qure Dr. Vinay Prasad Hem/onc disagrees with Drs. Ole Isacson Victor Sung Ed Wild Sarah Tabrizi prof. of Neurology about AMT-130. If you are a HD patient or family members Do you trust a Hem/onc or a Neurology professor"  
[X Link](https://x.com/anyuser/status/1986557400388862413)  2025-11-06T22:12Z [---] followers, [----] engagements


"$qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is important because it provides a specific influential viewpoint on current events based on the principles of free markets and free people aiming to shape public debate"  
[X Link](https://x.com/anyuser/status/1986604355144073317)  2025-11-07T01:19Z [---] followers, 50.3K engagements


"Based on this piece I think someone fairly influential is saying the FDA is on a hot seat and is an embarrassment to the 2nd term of Trumps presidency"  
[X Link](https://x.com/canoebrookbl/status/1986606997735944462)  2025-11-07T01:29Z [---] followers, [----] engagements


"$qure implications: VP replaced AA granted a buyout by an US BP at reasonable (not crazy) premium UniQure is Americanized [---] approved by the FDA ahead of EU/UK victory declared. End of drama $qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is important because it provides a specific influential viewpoint on current events based on the principles of free markets and free people aiming to shape public debate. https://t.co/KF9GPCzYNz $qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is"  
[X Link](https://x.com/anyuser/status/1986625743892455772)  2025-11-07T02:44Z [---] followers, [----] engagements


"$qure Fidelity close to 10% Vangard (buying) and $jpm (trimming) both close to 2%. All bought most shares after positive data. Senate hearing plus @WSJEditorials piece smacking the US FDA @US_FDA. High stake drama ready to explode and US BP ready to pick up $qure on sale. MAGA"  
[X Link](https://x.com/anyuser/status/1986830925771182220)  2025-11-07T16:19Z [---] followers, [----] engagements


"@US_FDA @RareDiseases $xbi $qure $bhvn after listening to the interview felt even less confident about the FDAs overall credibility and directions. What is your reaction 🔊 Running through the latest batch of National Priority Voucher recipients with Dr. Mundkur. More to come https://t.co/XG28B0PTF4 🔊 Running through the latest batch of National Priority Voucher recipients with Dr. Mundkur. More to come https://t.co/XG28B0PTF4"  
[X Link](https://x.com/anyuser/status/1986945684273299469)  2025-11-07T23:55Z [---] followers, [----] engagements


"$qure after almost [--] m we know [---] data were presented by Dr. Victor Sung at HSG [----] conference in Nashville and by Dr. Deborah Hall at Movement Disorder Society meeting in Hawaii if you find the abstracts and/or presentations please circulate. I did not find them"  
[X Link](https://x.com/canoebrookbl/status/1986957654565228978)  2025-11-08T00:43Z [---] followers, [----] engagements


"$xbi $bhvn $qure rumors or not"  
[X Link](https://x.com/anyuser/status/1987028074614133034)  2025-11-08T05:23Z [---] followers, [----] engagements


"@LogicalValueMx @DesertDweller93 @peter_mantas @biggercapital @uniQure_NV @US_FDA @RobertKennedyJr @HDA_tweeting @realDonaldTrump @VPrasadMDMPH@DrMakaryFDA I think what makes us all angry is this my version of science is the only version because I have power I can override anything even it is beyond my specialty and expertise attitude. Your power is given by all of us THE AMERICAN PEOPLE"  
[X Link](https://x.com/canoebrookbl/status/1987222548086726912)  2025-11-08T18:15Z [---] followers, [----] engagements


"@DesertDweller93 @peter_mantas @biggercapital @uniQure_NV @US_FDA @RobertKennedyJr @HDA_tweeting @realDonaldTrump @LogicalValueMx @VPrasadMDMPH @DrMakaryFDA $qure $xbi http://help4hd.org/speakup4hd @LogicalValueMx @DesertDweller93 @peter_mantas @biggercapital @uniQure_NV @US_FDA @RobertKennedyJr @HDA_tweeting @realDonaldTrump @VPrasadMDMPH@DrMakaryFDA I think what makes us all angry is this my version of science is the only version because I have power I can override anything even it is beyond my specialty and expertise attitude. Your power is given by all of us THE AMERICAN PEOPLE"  
[X Link](https://x.com/canoebrookbl/status/1987226394028540216)  2025-11-08T18:31Z [---] followers, [----] engagements


"$qure similar design to AMT-130: small ph [--] study with external control arm which led to Zolgensma AA and full approval and label extension supported by ph [--] studies. Why dont we get rid of AA and breakthrough therapy entirely and go back to the [--] under this FDA"  
[X Link](https://x.com/canoebrookbl/status/1987299210958676145)  2025-11-08T23:20Z [---] followers, [----] engagements


"@qure $xbi Let us hear from the far left equally harsh on the current FDA last paragraph highlighted the risk of only my version of science is science. Maybe CNN will have a more updated piece next week. https://www.cnn.com/2025/09/12/health/fda-advisory-committee-kff-health-news https://www.cnn.com/2025/09/12/health/fda-advisory-committee-kff-health-news"  
[X Link](https://x.com/canoebrookbl/status/1987319463767908671)  2025-11-09T00:40Z [---] followers, [----] engagements


"$qure I did not read the NYT piece when positive data came out. Reading it now a balanced view with strong support from non [---] investigators. But MM and VP do not need expert opinions. MM can not even pronounce some of the drugs that got his holy grails vouchers"  
[X Link](https://x.com/anyuser/status/1987326642793181612)  2025-11-09T01:09Z [---] followers, [----] engagements


"$qure $nvs $xbi another WSJ editorial board piece taking a jab @VPrasadMDMPH and @US_FDA. This time VP was even incompetent in his own specialty hem/onc by his poor judgement on Pluvicto. Shoutout to @POTUS to intervene directly There is HOPE for HD"  
[X Link](https://x.com/anyuser/status/1987396488113303683)  2025-11-09T05:47Z [---] followers, [----] engagements


"I watched VPs YouTube video criticizing the VISION trial of Pluvicto and encourage you to watch as well. I know how much more you will HATE VP after watching this video given the huge success of Pluvicto. He is truly a disgrace to the @US_FDA"  
[X Link](https://x.com/canoebrookbl/status/1987542311753171364)  2025-11-09T15:26Z [---] followers, [----] engagements


"Lutetium [---] PSMA - Problems with the Vision Trial via @YouTube Imagine what he is doing now with HD and $qure as if he is GOD. but actually knows NOTHING not even in oncology let alone HD and neurology https://youtu.be/pAsPzPt2avcsi=Nv3VnoGCMIznJQvo I watched VPs YouTube video criticizing the VISION trial of Pluvicto and encourage you to watch as well. I know how much more you will HATE VP after watching this video given the huge success of Pluvicto. He is truly a disgrace to the @US_FDA https://t.co/TlCKKNxcYQ https://youtu.be/pAsPzPt2avcsi=Nv3VnoGCMIznJQvo I watched VPs YouTube video"  
[X Link](https://x.com/canoebrookbl/status/1987544349539004783)  2025-11-09T15:34Z [---] followers, [----] engagements


"WSJ Opinion: Hits and Misses of the Week Another blow from WSJ @VPrasadMDMPH this time in video and mentioned VP and $qure. The countdown of VPs demise https://www.wsj.com/video/series/journal-editorial-report/wsj-opinion-hits-and-misses-of-the-week/EDC1EC6D-5214-4DD8-B0E3-738488930277 https://www.wsj.com/video/series/journal-editorial-report/wsj-opinion-hits-and-misses-of-the-week/EDC1EC6D-5214-4DD8-B0E3-738488930277"  
[X Link](https://x.com/canoebrookbl/status/1987680624724099303)  2025-11-10T00:36Z [---] followers, 13.5K engagements


"$qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS in his 1st term. If the deny of [---] is due to co. didnt run a sufficient study to prove substantial evidence of effectiveness the agencys efficacy review lacks statutory basis"  
[X Link](https://x.com/anyuser/status/1987903479667683634)  2025-11-10T15:21Z [---] followers, 33.1K engagements


"This means advocacy groups and biotech companies can sue the FDA CBER as the relevant underlying legislation the Public Health Service Act doesnt require proof of substantial effectiveness for biologicals. WSJ is not only attacking VP but lay the legal groundwork against him"  
[X Link](https://x.com/canoebrookbl/status/1987904662478205354)  2025-11-10T15:26Z [---] followers, [---] engagements


"$qure investors maybe disappointed by a less feisty call by mgmt I command their poise/willingness to continue to work with the FDA on AA path. With strong support from WSJ why not showing the good side Someone like my post can reach to top legislators directly from both side $qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS in his 1st term. If the deny of [---] is due to co. didnt run a sufficient study to prove substantial evidence of effectiveness the agencys efficacy review lacks statutory basis. https://t.co/H98hVmvLEu $qure pl read this WSJ"  
[X Link](https://x.com/anyuser/status/1987925025215967720)  2025-11-10T16:47Z [---] followers, [----] engagements


"$qure totally possible VP walks back from current FDA stance to keep his job. Assuming he is not too stupid and Robert P. Charrow the previous General Counsel of HHS during the 1st Trump administration gave him some legal advice publicly via WSJ"  
[X Link](https://x.com/anyuser/status/1987936740062228622)  2025-11-10T17:33Z [---] followers, [----] engagements


"$bhvn a bit more challenging for FDA to walk back even with strong support from Tom Philipson former Chairman WH Council of Eco. Advisor in this WSJ piece. $qure is a biological CBER simply does not have any legal ground to deny $qures request for an AA based BLA filing $qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS in his 1st term. If the deny of [---] is due to co. didnt run a sufficient study to prove substantial evidence of effectiveness the agencys efficacy review lacks statutory basis. https://t.co/H98hVmvLEu $qure pl read this WSJ opinion"  
[X Link](https://x.com/anyuser/status/1987986343893627320)  2025-11-10T20:50Z [---] followers, [----] engagements


"$qure I know how much you care about this important information as some of you reached out for clarification of biologicals. Looks like gene therapy should be part of it as Robert answering a readers comment. $qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS in his 1st term. If the deny of [---] is due to co. didnt run a sufficient study to prove substantial evidence of effectiveness the agencys efficacy review lacks statutory basis. https://t.co/H98hVmvLEu $qure pl read this WSJ opinion letter carefully written by Robert P. Charrow tied with @POTUS"  
[X Link](https://x.com/anyuser/status/1988264335651885213)  2025-11-11T15:15Z [---] followers, [----] engagements


"$qure this WSJ editorial board piece continues to draw significant attention from readers as you can see the number of comments up to today. @US_FDA . You can all get your voices heard directly on WSJ no matter if you are in the US or not. Time to action $qure WSJ editorial piece sided with biotech and said FDA shifts approval standards. An editorial piece is important because it provides a specific influential viewpoint on current events based on the principles of free markets and free people aiming to shape public debate. https://t.co/KF9GPCzYNz $qure WSJ editorial piece sided with biotech"  
[X Link](https://x.com/anyuser/status/1988268917601816581)  2025-11-11T15:33Z [---] followers, [----] engagements


"$qure an editorial piece on @ScienceMagazine and @Nature by Drs. Ole Isacson and Henry Miller could be as powerful as those WSJ editorial board pieces M.D.s and PhDs time for action @canoebrookbl @US_FDA https://t.co/UgtzZuJJh4 @canoebrookbl @US_FDA https://t.co/UgtzZuJJh4"  
[X Link](https://x.com/anyuser/status/1988273747326026046)  2025-11-11T15:52Z [---] followers, [----] engagements


"$qure once investors realized Robert Charrow former HHS general counsel just gave some serious legal advice to VP/CBER via WSJ and verified with AI research contact with Robert or other legal consultations $qure will be through the roof as the US FDA has no legal ground $qure I know how much you care about this important information as some of you reached out for clarification of biologicals. Looks like gene therapy should be part of it as Robert answering a readers comment. https://t.co/8gg1KZNo4p $qure I know how much you care about this important information as some of you reached out for"  
[X Link](https://x.com/anyuser/status/1988290907716939922)  2025-11-11T17:01Z [---] followers, [----] engagements


"$qure hope you did not all in or emotionally sold at the low You maybe able to recover some of your losses and get paid by the US FDA as even though we do not have all the information looks likely the drop was caused by a flip-flop FDA who has no legal grounds"  
[X Link](https://x.com/anyuser/status/1988303112512434431)  2025-11-11T17:49Z [---] followers, [----] engagements


"@AlecGaffney Anything on CBER and VP We all want VP fired or walk back on $qure as he was so incompetent even in oncology as he bashed Pluvictos VISION trial before its approval only to be embarrassed by the success and lifes saved by Pluvicto. VPs science is not the only version of sci"  
[X Link](https://x.com/anyuser/status/1988340585774928320)  2025-11-11T20:18Z [---] followers, [---] engagements


"Rick is a great guy Hope more positive changes on the CBER SIDE. $qure $xbi @LauraLoomer Rick Pazdur moving over to take the reins of CDER is a VERY BIG DEAL for the FDA. It may also be the trigger for more change. Rick Pazdur moving over to take the reins of CDER is a VERY BIG DEAL for the FDA. It may also be the trigger for more change"  
[X Link](https://x.com/anyuser/status/1988358766279225834)  2025-11-11T21:30Z [---] followers, [----] engagements


"$xbi $qure hope VP wont be around at the US FDA to feud with Rick The interpersonal dynamics between CBER's Prasad and CDER's Pazdur are going to be interesting to watch in the coming months as these old posts from Prasad's account (still available) vividly illustrate. https://t.co/lDQT6nygEc The interpersonal dynamics between CBER's Prasad and CDER's Pazdur are going to be interesting to watch in the coming months as these old posts from Prasad's account (still available) vividly illustrate. https://t.co/lDQT6nygEc"  
[X Link](https://x.com/anyuser/status/1988406846181593257)  2025-11-12T00:41Z [---] followers, [----] engagements


"FDA unveils new regulatory roadmap for bespoke drug therapies via @BioPharmaDive $qure did not read it yet is it real https://www.biopharmadive.com/news/fda-plausible-mechanism-pathway-n-of-1-crispr/805235/ https://www.biopharmadive.com/news/fda-plausible-mechanism-pathway-n-of-1-crispr/805235/"  
[X Link](https://x.com/canoebrookbl/status/1988755407133929857)  2025-11-12T23:46Z [---] followers, [----] engagements


"$qure it will be quite a bombshell if FDA said no AA but [---] approvable as the 1st one under this MM VP new FDA New Plausible Mechanism Pathway Maybe not as good as AA but you will get an approval. Case solved FDA unveils new regulatory roadmap for bespoke drug therapies https://t.co/C4M1lqmJc7 via @BioPharmaDive $qure did not read it yet is it real FDA unveils new regulatory roadmap for bespoke drug therapies https://t.co/C4M1lqmJc7 via @BioPharmaDive $qure did not read it yet is it real"  
[X Link](https://x.com/anyuser/status/1988783549680607664)  2025-11-13T01:38Z [---] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing